BBA
PTGX icon

Baader Bank Aktiengesellschaft’s Protagonist Therapeutics PTGX Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,300
Closed -$286K – 580
2025
Q3 		$286K Buy
+4,300
New +$244K 0.02% 399

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baader Bank Aktiengesellschaft's PTGX Position: Q4 2025 in Review

Baader Bank Aktiengesellschaft sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 4,300 shares — an estimated $286K sold.

Baader Bank Aktiengesellschaft first reported a position in PTGX in Q3 2025 and held it in 1 quarter. The position peaked at $286K in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Baader Bank Aktiengesellschaft reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 4,300 Protagonist Therapeutics shares in Q4 2025, an estimated $286K.
  • Baader Bank Aktiengesellschaft first reported a position in Protagonist Therapeutics in Q3 2025 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Protagonist Therapeutics position peaked at $286K in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q4 2025, filed 5 Feb 2026.